Listed

Dominari Holdings Inc.: Form 10-K for the period ended Dec 31, 2022

Filed with the SEC on Mar 31, 2023 and accepted by EDGAR at Mar 31, 2023, 14:49 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2022-01-01 to 2022-12-31$830.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2022-01-01 to 2022-12-31$11.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2022-01-01 to 2022-12-31−$14.3mus-gaap:OperatingIncomeLoss
Net income12 months2022-01-01 to 2022-12-31−$22.1mus-gaap:NetIncomeLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−$4.91us-gaap:EarningsPerShareDiluted
Basic EPS12 months2022-01-01 to 2022-12-31−$4.91us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2022-01-01 to 2022-12-315,334,075 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2022-01-01 to 2022-12-31−$10.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Share repurchases12 months2022-01-01 to 2022-12-31$3.1mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2022-12-31$33.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$50.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$76.2mus-gaap:Assets
Current liabilitiesAt period end2022-12-31$1.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-12-31$2.5mus-gaap:Liabilities
Shareholders' equityAt period end2022-12-31$73.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-23-025306. Last ingested by Listed: Nov 6, 2026, 17:26 ET. Listed shows no prices and gives no investment advice.